Disease Areas

News and analysis on disease research and diagnostics.

The NGS-based test, which was approved by the FDA in June, will be now available to the insurers' members, who have non-small cell lung cancer, in four states.

Several commercial NIPT providers in the US said they are planning to participate in the new program.

BioSequence is looking to raise the profile of its genomic offering among clinicians, and to strengthen its case for reimbursement.

 

The two companies plan to secure required initial regulatory approvals in individual African territories before expanding to other areas in the region.

The NIH is aiming to fund projects evaluating the clinical potential of cancer biomarker assays that are already validated for research use.